We all know that:
- enrolling of participants in Lavender is currently suspended
- that a significant number of the projected 184 girls were already receiving trofinetide
- according to the Lilac trial, girls in 9 (of 14) locations have progressed into Lilac
I'm wondering, given:
- the crazy world we are now living in, and
- the Orphan Drug Designation applying to Rett Syndrome
whether Acadia considers that the results from Lilac are sufficiently positive to seek permission from the FDA to not resume enrollments in Lavender and conclude the phase 3 trial?
ACADIA TALKS TROFINETIDE, page-62
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |